Build status - In Progress
Found 36 Lymphoma trials
A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Featured study
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.
The primary objective of this study is to evaluate the safety of retreatment of patients with CTL019/CTL119 therapy who have experienced late relapse of lymphoma.
Please refer to Protocol Section 2.0. Please refer to Protocol Section 12.0 Please refer to Protocol Section 12.0
This is an observational study to determine what types of medications patients take to treat MCL as well as how patients respond to those medications.
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the …
Please choose between Voice or SMS based delivery of verification code
or